To appraise guidelines on cardiovascular risk assessment to guide selection of screening interventions for a health check.
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of mortality in Western society, accounting for approximately one-third of total mortality (1) . Much of the burden of CVD can potentially be relieved by primary prevention, that is, reducing CVD incidence in the apparently healthy population. Detecting and treating those at highest CVD risk is regarded as an essential complement to a population-based approach (2) . The primary care physician plays a pivotal role in providing prevention on the individual level and is thus essential for the success rate of this strategy. However, most physicians find implementing even rudimentary preventive services difficult, and the management of increased CVD risk remains suboptimal (3) . Although historically controversial (4, 5) , cardiovascular health checks have now been widely accepted as a means to efficiently detect high-risk individuals in primary care practice. As a result of the Diabetes, Heart Disease and Stroke pilot studies, UK citizens aged 40 to 74 years will be offered a cardiovascular health check every 5 years. This includes a questionnaire on risk factors and measurement of weight, hip to waist ratio, blood pressure, and total cholesterol level. People at high risk for developing diabetes undergo measurement of glucose levels (6) . In the United States, cardiovascular health checks are already common practice as part of the periodic health examination (7) . In the absence of a blueprint for the content of cardiovascular health checks, decisions on selection of appropriate individual screening interventions should be guided by the best available medical evidence. For translating research into clinical practice, clinical practice guidelines are commonly assumed to be the remedy. Clinical practice guidelines are defined by the Institute of Medicine as "systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances" (8) . However, guidelines on the same topic can conflict with each other, and concern exists about the quality and independence of guidelines. Therefore, clinicians should be able to identify guidelines that are developed systematically and provide transparent estimates of the benefits and harms of interventions (9, 10) . Various notable organizations have developed guidelines containing recommendations for cardiovascular screening to prevent a first CVD event. Although guideline compendiums exist (11) , it is not feasible for the busy physician to identify and critically appraise all possible relevant guidelines. We therefore conducted a systematic review of guidelines containing recommendations for cardiovascular risk assessment in apparently healthy adults, that is, adults free of established CVD who are not already receiving treatment for high-risk conditions such as diabetes, hypertension, and hypercholesterolemia. We appraised guidelines using a validated instrument and assessed potential conflicts of interest. Finally, we examined recommendations from rigorously developed guidelines in detail to guide primary care physicians in deciding which screening interventions to use within a cardiovascular health check.
METHODS

Data sources and guideline selection
To identify appropriate guidelines, a literature search was performed by using MEDLINE and CINAHL between January 1, 2003, and May 2, 2009. We supplemented this by searching the
RESULTS
The search retrieved 1984 titles, of which 323 were identified as potentially eligible. Many were excluded on the basis of the abstract (n=209) and on review of the full report (n=87). Finally, 27 guidelines relevant to cardiovascular risk assessment were included ( Figure 1 ). Table 1 summarizes the selected guidelines, together with the rigor score and conflict of interest results, categorized by the following screen-detectable conditions: total cardiovascular risk, dyslipidemia, hypertension, and dysglycemia (diabetes mellitus, impaired glucose tolerance, and/or impaired fasting glucose). Eleven guidelines did not report that they were developed independently from funding organizations or have a statement about conflicts of interest of group members. The development of 2 guidelines (from the New Zealand Guidelines Group [NZGG] and the National Health and Medical Research Council [NHMRC]) was funded by external governmental sources. Guidelines from the Canadian Diabetes Association (CDA) and the International Diabetes Federation (IDF1 and IDF2) were financially supported by industry partners. Although sponsors did not take part in the development of these guidelines, commercial organizations were allowed to comment on draft versions of the IDF1. Only 2 guidelines (from the American Heart Association [AHA1] and the CDA) reported that recusal of group members with conflicts of interest was accomplished when relevant areas were under discussion. Seventeen of the 27 guidelines had an average rigor score equal to or greater than 50%. Recommendations for total cardiovascular risk assessment extracted from these guidelines are demonstrated in Table 2 , excluding the recommendation of the AHA2 guidelines that did not explicitly describe treatment thresholds. Advice concerning screening primarily for single risk factors (dyslipidemia, hypertension, and dysglycemia) are tabulated in Tables 3, 4 , and 5.
Areas of agreement
Recommendations of 16 of 17 guidelines supported risk assessment. In general, there was consensus on how screening tests should be administered to the target population. A selective Figure 1 . Summary of guideline search and review process. Numbers of guidelines at each step of the process are indicated. Group totals may exceed the reported numbers for the excluded articles at abstract and full text level because several reasons for exclusion were allowed. CMA indicates Canadian Medical Association; CVD, cardiovascular disease; and NGC, National Guideline Clearinghouse. screening approach based on prior knowledge of patient characteristics (record-based screening) or during non-preventive patient visits (case finding or opportunistic screening) was advocated in 10 of 17 guidelines. A mass screening approach was suggested as an alternative by only 1 guideline (from the National Heart, Lung, and Blood Institute [NHLBI]). Many guidelines recommended integrating age, sex, smoking, blood pressure, and lipid levels into total cardiovascular risk assessment by using prediction models (Tables 2 and 3 ). In only 2 hypertension guidelines (from the US Preventive Services Task Force [USPSTF2] and the AHA2 guidelines) were treatment decisions merely guided by elevated blood pressure levels ( Table 4 ). The recommended prediction models were all based on the concept that CVD is best predicted by multiple risk factors and that these risk factors interact. If a risk score was not recommended as a primary screening test, it was frequently used to guide treatment in a second stage for individuals with elevated single risk factors (USPST1 and NHLBI guidelines). Thresholds for initiation of treatment were based on short-term (5-or 10-year) risk for CVD, with exceptions often made for those with extreme levels of single risk factors. In general, the same thresholds across guidelines were used for the initiation of treatment with aspirin, statins, and antihypertensives. The guideline from the European Society of Cardiology for total cardiovascular risk assessment (ESC1) used a higher threshold for the use of aspirin because of the risk for major gastrointestinal tract bleeding. The ESC1 guideline may represent a common, cautious European viewpoint. However, we did not observe a more conservative attitude with respect to preventive treatments among the European guidelines compared with the others. Guidelines that specifically covered dysglycemia screening were mainly focused on selecting individuals for interventions to lower glucose levels and did not report or were short on initiation of statin and aspirin therapy ( Table 5 ). Guidance for these treatments was based on single risk factors, and none of the recommendations contained models predicting CVD. Fasting glucose level was usually the test of first choice, except for 1 guideline (ESC3) in which an antecedent risk score for developing type 2 diabetes mellitus was recommended. Although guidelines did not make firm statements about screening intervals, frequently reported periods of screening for individuals at low risk were 5 years for total cardiovascular risk and dyslipidemia screening, 2 years for hypertension screening, and 3 years for dysglycemia screening. Only 2 guidelines based these intervals on modelling studies (NZGG and USPSTF3).
Areas of disagreement
We found no consensus on target populations for screening among the recommendations (Tables  2, 3 (Table 5 ) varied in strength. For example, for a 60-year-old patient without risk factors, screening could both be not supported and recommended at the same time, depending on which guideline the physician follows. Discrepancies in decision making could also occur with regard to the initiation of treatment guided by total cardiovascular risk ( Table 2) . Apart from differences in thresholds indicating high risk, recommended risk models varied over the use of datasets, predictors, and endpoints, including fatal and non-fatal CVD outcomes. For example, the NICE, SIGN, CCS, and NHLBI guidelines all used a threshold of 20% to define high risk. The NICE guidelines recommended the 1991 Framingham model using coronary artery disease and stroke events as a composite endpoint, whereas the CCS and NHLBI guidelines used Framingham models for predicting coronary artery disease alone(ie, without stroke). The SIGN guideline endorsed the ASSIGN score, which includes coronary artery disease, heart failure, aortic aneurysm, peripheral arterial disease, and stroke. Because of this lack of consistency, making comparisons of recommended indications for aspirin, statin, and antihypertensive therapy and intensive lifestyle changes is not straightforward.
COMMENT
We identified 27 guidelines involving cardiovascular risk assessment that could be performed within a cardiovascular health check. A great variation in rigor of development and transparency about conflicts of interest was found among the guidelines. Guidelines on screening for total cardiovascular risk and dyslipidemia embraced, to a different extent, decision making based on multiple risk factors. This approach contrasted with the recommendations for hypertension and dysglycemia screening, which focused on single risk factors. Most of the guidelines supported a selective screening strategy. We found differences between guidelines with respect to the selection of target groups, screening tests in addition to those for major CVD risk factors, and treatment thresholds. Different statements about strength were given to recommendations that considered comparable patient populations with respect to dysglycemia screening. No firm recommendations could be made for screening intervals in people at low risk for developing a first cardiovascular event.
Previously published reviews of CVD prevention guidelines were not systematically performed or did not use a validated instrument to assess the quality of identified guidelines (43, 44) . We used a sensitive search strategy to identify guidelines and the AGREE instrument to select guidelines of considerable quality. This article can therefore be of additional value to already available guideline compendiums and libraries such as the US National Guideline Clearinghouse and the UK National Library for Health because these libraries depend on submissions by guideline organizations. Although a guideline synthesis tool can be found on the National Guideline Clearinghouse Web site (45) , this tool is only available for a sample of US guidelines. Despite a number of strengths, there are several limitations that could have biased our findings. First, the AGREE instrument considers the whole guideline and is not intended for individual recommendations. However, a global appraisal will probably reflect the quality of the individual recommendations to some extent. Second, AGREE evaluates a guideline's construction process and not the quality of its content. It is beyond the scope of this review to appraise the quality of the evidence underpinning the recommendations. However, an analysis of underlying evidence should be considered when evaluating guidelines. One would expect that the quality of the development methods correlates with the quality of the content, but it may be possible to create a solid guideline with a poor process. Third, only 2 reviewers rated the AGREE rigor items, and a more precise estimate would be obtained if we could have used more resources. Finally, our search strategy's sensitivity could be improved. We did not use a search engine for an Internet search, and therefore we might have missed some eligible guidelines.
The finding that many guidelines recommended multivariable risk assessment conforms with historical developments. The rationale of its use is explained by studies showing that arbitrary elevations of single risk factors are of little clinical relevance when they are interpreted separately from other risk factors (46) . The performance of multivariable risk assessment mainly depends on the selection of appropriate risk predictors. Prediction models using the traditional major risk factors may be updated through inclusion of emerging risk factors (47) . However, the additional prognostic value is often questionable (48, 49) . Few of the reviewed guidelines used a prediction model incorporating 1 or more of the emerging risk factors. The value of general statements about their contribution to risk seems ambiguous if consistency of health care is intended. Implementation of cardiovascular risk assessment into practice has been shown to be difficult (50) . It is questionable whether the generally recommended opportunistic screening strategy could overcome this problem. Arguments in favour of opportunistic screening originate from disappointing results of population based periodic health examinations and nurse-led cardiovascular health checks (5, 51, 52) . Although health information technology may in part solve difficulties (53), the sheer volume of preventive care tasks per patient visit would put an overwhelming pressure on the workload of primary care physicians (54) . Periodically inviting individuals for a preventive visit using already recorded determinants could be a valuable alternative. The workload and cost-effectiveness of this strategy will depend on risk factor distributions in the selected target populations and applied thresholds that indicate elevated risk. Given the controversy about target populations, treatment thresholds, and screening intervals, we advocate a decision-analytic approach to resolve these issues (55) . Although guidelines on total cardiovascular risk, dyslipidemia, and hypertension all agreed on added value with screening, those on screening for dysglycemia sometimes disagreed. The case for dysglycemia screening has been uncertain in the absence of randomized trials but becomes stronger with the rising prevalence of overweight (56) . Because CVD is by far the leading cause of mortality in persons with diabetes mellitus, preventing CVD seems more crucial than reducing microvascular complications. Although intensive lowering of glucose levels in longstanding diabetes has not been shown to reduce CVD, in patients with newly diagnosed diabetes it may be beneficial (57, 58) . The efficacy of statins has been shown in a meta-analysis of 14 randomized controlled trials (59) . The use of aspirin therapy in diabetes, however, is still controversial (60, 61) . Included guidelines were predominantly focused on selection of individuals for therapy to lower glucose levels but were not unanimous with regard to statins. Some guidelines advised that all patients with diabetes should receive a statin, whereas most allocated statins only to those with raised cholesterol levels in addition to diabetes. However, sustained benefits of statins are seen even in diabetic patients with low cholesterol levels (59) , and thus it is argued that the decision for statin therapy in diabetes should also be based on total cardiovascular risk irrespective of initial cholesterol levels (62) .
Recommended risk models do not incorporate dysglycemia as a covariate or perform poorly in estimating CVD risk in diabetes (62, 63) . Prediction models specifically developed for people with dysglycemia (64,65) exist but have to be validated. Integration of dysglycemia screening within a cardiovascular health check thus remains complex. Some guidelines provided recommendations to select high-risk individuals for aspirin use.
Recommended treatment thresholds for aspirin were predominantly the same as those for statins and fixed according to sex and age. These recommendations contrast with the recent conclusions of the USPSTF (66), which established its guidance on an assessment of the net benefit of aspirin, determined by the potential preventable number of CVD events and the potential harm due to gastrointestinal tract hemorrhages. The USPSTF's thresholds for aspirin use depend on age and sex because the risk for serious bleeding increases with age and among men. The approach for aspirin use as demonstrated in the USPSTF guideline could lead to more individualized decision making. However, this approach can be made more sophisticated through expression of the benefit and harm in utility measures and might then also be applicable to the provision of other preventive treatments.
CONCLUSIONS
We identified guidelines providing recommendations for various screening interventions that can be performed within cardiovascular health checks. By using different recommendations, there are several ways to integrate multiple screening interventions into a single program. Although methods for guideline adaptation are available (10), our purpose was not to create one international set of recommendations. Nevertheless, physicians can easily adopt the presented recommendations applicable to their own health context. However, they should be wary of the differences, which can have important consequences for selection of individuals for preventive interventions (67) . In addition, physicians should be able to balance the utility and disutility of potential lifelong preventive treatment. Complete and unbiased information on benefits and harms is thus desirable. Transparency about how judgments have been made within guidelines allows physicians to make informed decisions on adopting recommendations (68) . Disclosure of conflicts of interest allows the industry influence on guideline development and the professional integrity of guideline group members to be assessed (69) . The AGREE rigor scores of many guidelines demonstrated poor quality, and several guidelines lacked statements about conflicts of interest. We therefore encourage physicians to use the tabulated guidelines with higher AGREE rigor scores and unambiguous declarations about conflict of interest from this review for organizing their cardiovascular health checks. 
